Ultragenyx Reports Third-Quarter Revenue of $173 Million
Revenue rose 8% year over year to $173 million. The company reported a net loss of $118 million and diluted loss per share of $1.16, compared with a $180 million loss and $1.81 per share a year earlier.
Ultragenyx Pharmaceutical Inc. reported third-quarter 2026 revenue of $173 million, up 8% from $160 million a year earlier, and a net loss of $118 million compared with a $180 million loss. Diluted loss per share was $1.16, versus $1.81 in the prior-year quarter.Financial HighlightsBusiness Highlig…